International multicenter experience in the treatment of invasive aspergillosis in immunocompromised cancer patients
CONCLUSIONS:Based on international experience in immunocompromised cancer patients with IA, primary therapy with voriconazole-containing regimen is associated with improved response and survival compared with non-voriconazole amphotericin B based regimen.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research
More News: Abelcet | Aspergillosis | Brazil Health | Cancer | Cancer & Oncology | Hematology | Infectious Diseases | Japan Health | Lebanon Health | Leukemia | Lymphoma | Middle East Health | Myeloma | Study